Cannabidiol-Assisted Learning for Managing Generalized Anxiety Disorder

This randomized, double-blind, placebo-controlled clinical trial investigates the use of Food and Drug Administration (FDA)-approved cannabidiol (EPIDIOLEX®) as an adjunct to cognitive behavioral therapy (CBT) in adults with generalized anxiety disorder (GAD). The study aims to evaluate whether cannabidiol-assisted CBT enhances emotion regulation via dorsomedial prefrontal cortex (dmPFC) activation and improves anxiety symptom outcomes compared to CBT with placebo.

NCT Number	NCT07123467
Lead Sponsor	Wayne State University Collaborators: National Institute of Mental Health (NIMH)
Conditions	Generalized Anxiety Disorder (GAD), Anxiety Disorders
Enrollment	90 participants
Start Date	2025-11-03
Primary Completion	2027-08-31 (estimated)
Study Completion	2027-08-31 (estimated)
Updated on ClinicalTrials.gov	2026-03-09